Mode
Text Size
Log in / Sign up

Gastroesophageal Reflux Disease

Part of Esophageal Diseases

7 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Gastroesophageal Reflux Disease

76 trials tracked for Gastroesophageal Reflux Disease: 35 in phase 3 or 4 and 4 with published results. The most-cited published study has 49 citations.

76Trials tracked
35Phase 3 & 4
0Recruiting
4With published results
Phase distribution
Phase 4 10 Phase 3 25 Phase 2 9 Phase 1 6 Other / NA 26
  1. Phase 3 Gastroesophageal Reflux Treatment in Scleroderma Completed · 49 cited
  2. Phase 3 A Double-blind Comparative Study of the Efficacy and Safety of E3810 10mg Once and Twice Daily in Maintenance Therapy for PPI Resistant Gastroesophageal Reflux Disease Patients Completed · 29 cited
  3. Phase 3 Compound Sodium Alginate Double Action Chewable Tablet Symptomatic Relief Study Completed · 28 cited
  4. Phase 4 Pharmacokinetics of Immediate-Release vs. Delayed-Release Omeprazole in Gastroparesis Completed · 4 cited
  5. Phase 4 Do Laryngeal Tissue Changes in Patients Suspected of Having Laryngopharyngeal Reflux Predict Response to Treatment? Completed
  6. Phase 4 Dexlansoprazole in Asian Participants With Gastroesophageal Reflux Disease Completed
Show 44 more trials
  1. Phase 4 Implementation of PPI Medication PGX Testing Completed
  2. Phase 4 Phase IV Study of the Impact of Dietary Fibers on Symptoms and Esophageal Motility in Patients With Non-erosive GERD Completed
  3. Phase 4 Role of Pepsin Assay in Wheezy Infants Completed
  4. Phase 4 Safety and Efficacy of Lansoprazole in Patients With Reflux Disease Completed
  5. Phase 4 Local Phase IV, Gastroesophageal Reflux Disease (GERD) Sleep Study US Completed
  6. Phase 4 To Assess the Efficacy of Esomeprazole 20mg Once Daily in Subjects Who Still Had Heartburn After Receiving Rabeprazole Completed
  7. Phase 4 A Study of Nexium (Esomeprazole) 40 mg Once Daily in Subjects With Symptoms of Gastroesophageal Reflux Disease (GORD) After Treatment With a Full Dose of Proton Pump Inhibitor (PPI) Completed
  8. Phase 3 Efficacy and Safety of Dexlansoprazole on Heartburn Relief in Chinese Patients Completed
  9. Phase 3 Compound Sodium Alginate Double Action Chewable Tablets 4-hour Esophageal pH Study in GERD Patients Completed
  10. Phase 3 Genotype-tailored Treatment of Symptomatic Acid-Reflux in Children With Uncontrolled Asthma Completed
  11. Phase 3 Safety and Efficacy of Dexlansoprazole Modified Release Formulation to Treat Heartburn Completed
  12. Phase 3 Efficacy of Dexlansoprazole MR on Heartburn Control in Participants Previously Receiving Twice Daily Proton Pump Inhibitor Therapy Completed
  13. Phase 3 Study Evaluating Pantoprazole in Children With GERD Completed
  14. Phase 3 A Study of Dexlansoprazole Modified Release Formulation to Treat Night Heartburn Completed
  15. Phase 3 Medical Treatment for Gastroesophageal Reflux Disease (GERD) in Preterm Infants Completed
  16. Phase 3 Phase III Study Comparing Zegerid® With Losec® for the Relief of Heartburn Associated With Gastroesophageal Reflux Disease Completed
  17. Phase 3 The Role Of Gastroesophageal Reflux Disease (GERD) in Eosinophilic Esophagitis Completed
  18. Phase 3 Study Evaluating the Efficacy and Safety of Pantoprazole in Infants With Symptomatic Gastroesophageal Reflux Disease (GERD) Completed
  19. Phase 3 Safety and Efficacy Study of Axid Use in Infants Suffering From Gastroesophageal Reflux Disease (GERD) Completed
  20. Phase 3 Esomeprazole (NEXIUM) vs. Surgery Completed
  21. Phase 3 Study Evaluating Pantoprazole in Children With Gastroesophageal Reflux Disease (GERD) Completed
  22. Phase 3 Safety and Efficacy of Dexlansoprazole Modified Release Formulation to Treat Gastroesophageal Reflux Disease Completed
  23. Phase 3 Study Evaluating Pantoprazole Sodium Enteric-Coated Spheroid Suspension In Infants With Presumed GERD Completed
  24. Phase 3 Safety and Efficacy of Rabeprazole in Infants With Gastroesophageal Erosive Reflux Disease (GERD) Completed
  25. Phase 3 Open Label Safety Study of Enteric-Coated Spheroid Suspension in Infants Aged Less Than 12 Months With Presumed Gastroesophageal Reflux Disease (GERD) Completed
  26. Phase 3 Safety and Quality of Life Study of Dexlansoprazole Modified Release Formulation to Treat Heartburn Completed
  27. Phase 3 Role of Pain Modulation in GERD Patients Who Failed Standard Dose PPI Completed
  28. Phase 3 Efficacy and Safety of Dexlansoprazole Modified Release Formulation to Treat Heartburn Completed
  29. Phase 3 Study Evaluating Pantoprazole in Neonates and Preterm Infants With GERD Completed
  30. Phase 2 Maintenance Intermittent Therapy for Symptomatic GERD Patients Completed
  31. Phase 2 Comparison of Vonoprazan to Esomeprazole in Participants With Symptomatic GERD Who Responded Partially to a High Dose of Proton Pump Inhibitor (PPI) Completed
  32. Phase 2 Treatment of Gastroesophageal Reflux Disease in 12-16 Year Old Patients With Rabeprazole Completed
  33. Phase 2 Safety and Efficacy of Dexlansoprazole Delayed-Release Capsules for Healing of Erosive Esophagitis and Maintenance of Healed Erosive Esophagitis and Relief of Heartburn in Adolescents Completed
  34. Phase 2 A Study to Estimate Effect of 4 Different Doses of AZD3355 on Reflux Episodes, Which Patients With Gastroesophageal Reflux Disease (GERD) May Experience Completed
  35. Phase 2 Investigate the Effect of Different Doses of Lesogaberan (AZD3355) as add-on to PPI in GERD Patients With Partial Response to PPI Completed
  36. Phase 2 Safety and Efficacy of Dexlansoprazole Delayed-Release Capsules in Treating Symptomatic Non-Erosive Gastroesophageal Reflux Disease in Adolescents Completed
  37. Phase 2 A Trial of IW-3718 for 8 Weeks in Patients With Symptomatic Gastroesophageal Reflux Disease (GERD) Completed
  38. Phase 2 Selective 5-HT4 Receptor Agonist and Proton Pump Inhibitor (PPI) in Subjects With Gastroesophageal Reflux Disease (GERD) Completed
  39. Phase 1 A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Vonoprazan in Adolescents With Symptomatic Gastroesophageal Reflux Disease Completed
  40. Phase 1 Pharmacokinetic and Safety of Dexlansoprazole in Adolescents With Gastroesophageal Reflux Disease Completed
  41. Phase 1 Sensory Evaluation of Dexlansoprazole Delayed-Release Orally Disintegrating Tablets Completed
  42. Phase 1 Study to Evaluate the Pharmacokinetics and Safety of Dexlansoprazole in Pediatric Subjects With Symptomatic Gastroesophageal Reflux Disease Completed
  43. Phase 1 PK Study With Pantoprazole in Obese Children and Adolescents Completed
  44. Phase 1 A Study to Evaluate Vonoprazan in Children Who Have Symptomatic Gastroesophageal Reflux Disease Completed

Showing the 50 most-cited and recently-updated of 76 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.

Questions about Gastroesophageal Reflux Disease

Why do some adults with systemic sclerosis still have GERD despite taking acid reducers?

Adults with systemic sclerosis often have reflux that acid reducers cannot stop because their esophagus and stomach muscles do not squeeze properly, causing acid to linger longer in the body.

Full answer →
Can magnetic sphincter augmentation devices erode after sleeve gastrectomy surgery for GERD?

Yes, magnetic sphincter augmentation devices can erode after sleeve gastrectomy, with a significantly higher erosion rate (3.8%) compared to non-bariatric populations (0.1%-0.3%).

Full answer →